160 related articles for article (PubMed ID: 37679656)
1. Impact of Apparatus and Adapter on In vitro Drug Release of Ophthalmic Semisolid Drug Products.
Mekjaruskul C; O'Reilly Beringhs A; Qin B; Wang Y; Chowdhury P; Lu X
Pharm Res; 2023 Sep; 40(9):2239-2251. PubMed ID: 37679656
[TBL] [Abstract][Full Text] [Related]
2. In vitro release testing method development for ophthalmic ointments.
Bao Q; Shen J; Jog R; Zhang C; Newman B; Wang Y; Choi S; Burgess DJ
Int J Pharm; 2017 Jun; 526(1-2):145-156. PubMed ID: 28461266
[TBL] [Abstract][Full Text] [Related]
3. Perspectives on Physicochemical and In Vitro Profiling of Ophthalmic Ointments.
Bao Q; Burgess DJ
Pharm Res; 2018 Oct; 35(12):234. PubMed ID: 30324424
[TBL] [Abstract][Full Text] [Related]
4. Influence of drug loading and type of ointment base on the in vitro performance of acyclovir ophthalmic ointment.
Al-Ghabeish M; Xu X; Krishnaiah YS; Rahman Z; Yang Y; Khan MA
Int J Pharm; 2015 Nov; 495(2):783-91. PubMed ID: 26343911
[TBL] [Abstract][Full Text] [Related]
5. In vitro and ex vivo correlation of drug release from ophthalmic ointments.
Bao Q; Newman B; Wang Y; Choi S; Burgess DJ
J Control Release; 2018 Apr; 276():93-101. PubMed ID: 29518465
[TBL] [Abstract][Full Text] [Related]
6. Impact of active pharmaceutical ingredient variables and oleaginous base on the in vitro drug release from ophthalmic ointments: An investigation using dexamethasone as a model drug.
Mekjaruskul C; O'Reilly Beringhs A; Qin B; Wang Y; Lu X
Int J Pharm; 2024 Jun; 658():124184. PubMed ID: 38692497
[TBL] [Abstract][Full Text] [Related]
7. Physicochemical attributes and dissolution testing of ophthalmic ointments.
Bao Q; Jog R; Shen J; Newman B; Wang Y; Choi S; Burgess DJ
Int J Pharm; 2017 May; 523(1):310-319. PubMed ID: 28344172
[TBL] [Abstract][Full Text] [Related]
8. Influence of in vitro release methods on assessment of tobramycin ophthalmic ointments.
Patere S; Newman B; Wang Y; Choi S; Mekjaruskul C; Jay M; Lu X
Int J Pharm; 2020 Nov; 590():119938. PubMed ID: 33011250
[TBL] [Abstract][Full Text] [Related]
9. An Analytical Target Profile for the Development of an In Vitro Release Test Method and Apparatus Selection in the Case of Semisolid Topical Formulations.
Szoleczky R; Kovács A; Berkó S; Budai-Szűcs M
Pharmaceutics; 2024 Feb; 16(3):. PubMed ID: 38543207
[TBL] [Abstract][Full Text] [Related]
10. Formulation and process factors influencing product quality and in vitro performance of ophthalmic ointments.
Xu X; Al-Ghabeish M; Rahman Z; Krishnaiah YS; Yerlikaya F; Yang Y; Manda P; Hunt RL; Khan MA
Int J Pharm; 2015 Sep; 493(1-2):412-25. PubMed ID: 26231106
[TBL] [Abstract][Full Text] [Related]
11. Formulation characteristics and in vitro release testing of cyclosporine ophthalmic ointments.
Dong Y; Qu H; Pavurala N; Wang J; Sekar V; Martinez MN; Fahmy R; Ashraf M; Cruz CN; Xu X
Int J Pharm; 2018 Jun; 544(1):254-264. PubMed ID: 29684560
[TBL] [Abstract][Full Text] [Related]
12. Physicochemical attributes of white petrolatum from various sources used for ophthalmic ointment formulations.
Bao Q; Morales-Acosta MD; Burgess DJ
Int J Pharm; 2020 Jun; 583():119381. PubMed ID: 32360506
[TBL] [Abstract][Full Text] [Related]
13. Use of Drug Release Testing to Evaluate the Retention of Abuse-Deterrent Properties of Polyethylene Oxide Matrix Tablets.
Meruva S; Rezaei L; Thool P; Donovan MD
AAPS PharmSciTech; 2020 Oct; 21(7):270. PubMed ID: 33025237
[TBL] [Abstract][Full Text] [Related]
14. In Vitro Drug Release Testing Method For Nepafenac Ophthalmic Suspension.
Gupta PK; Pancholi SS; Das P
J Pharm Sci; 2024 Apr; 113(4):1061-1067. PubMed ID: 38042345
[TBL] [Abstract][Full Text] [Related]
15. A comprehensive approach to qualify and validate the essential parameters of an in vitro release test (IVRT) method for acyclovir cream, 5.
Tiffner KI; Kanfer I; Augustin T; Raml R; Raney SG; Sinner F
Int J Pharm; 2018 Jan; 535(1-2):217-227. PubMed ID: 28935255
[TBL] [Abstract][Full Text] [Related]
16.
Kulkarni M; Potdar S; Date AA; Marfatiya A
Assay Drug Dev Technol; 2021; 19(2):75-84. PubMed ID: 33035072
[No Abstract] [Full Text] [Related]
17. Influence of Manufacturing Process Variables on the Properties of Ophthalmic Ointments of Tobramycin.
Patere S; Newman B; Wang Y; Choi S; Vora S; Ma AWK; Jay M; Lu X
Pharm Res; 2018 Jul; 35(9):179. PubMed ID: 30046909
[TBL] [Abstract][Full Text] [Related]
18. Development of a Discriminative In Vitro Release Test for Rivastigmine Transdermal Patches Using Pharmacopeial Apparatuses: USP 5 and USP 6.
Simon A; Amaro MI; Healy AM; Cabral LM; de Sousa VP
AAPS PharmSciTech; 2017 Oct; 18(7):2561-2569. PubMed ID: 28224389
[TBL] [Abstract][Full Text] [Related]
19. Drug release from semisolid dosage forms: a comparison of two testing methods.
Petró É; Paál TL; Erős I; Kenneth AS; Baki G; Csóka I
Pharm Dev Technol; 2015 May; 20(3):330-6. PubMed ID: 24328512
[TBL] [Abstract][Full Text] [Related]
20. In vitro biorelevant models for evaluating modified release mesalamine products to forecast the effect of formulation and meal intake on drug release.
Andreas CJ; Chen YC; Markopoulos C; Reppas C; Dressman J
Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):39-50. PubMed ID: 26391972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
